AVEO Pharmaceuticals (STU:VPA1) COGS-to-Revenue : 0.13 (As of Sep. 2022)

View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals COGS-to-Revenue?

AVEO Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2022 was €4.00 Mil. Its Revenue for the three months ended in Sep. 2022 was €30.75 Mil.

AVEO Pharmaceuticals's COGS to Revenue for the three months ended in Sep. 2022 was 0.13.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. AVEO Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2022 was 86.98%.

AVEO Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for AVEO Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals COGS-to-Revenue Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

COGS-to-Revenue

Get a 7-Day Free Trial

0.11

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
COGS-to-Revenue	Get a 7-Day Free Trial															0.11	0.12	0.12	0.12	0.13

AVEO Pharmaceuticals COGS-to-Revenue Calculation

AVEO Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2021 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4.192	/	37.431
	=	0.11

AVEO Pharmaceuticals's COGS to Revenue for the quarter that ended in Sep. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4.003	/	30.753
	=	0.13

AVEO Pharmaceuticals (STU:VPA1) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

AVEO Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2022 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	4.003 / 30.753
	=	86.98 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

AVEO Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

AVEO Pharmaceuticals (STU:VPA1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines